Cargando…

Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors

BACKGROUND: Few studies have focused on the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic colorectal cancer. Recognizing differences in prognosis and chemotherapeutic efficacy based on metastasized organs may help in optimiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Koshiro, Osumi, Hiroki, Yoshino, Koichiro, Nakayama, Izuma, Fukuoka, Shota, Ogura, Mariko, Wakatsuki, Takeru, Ooki, Akira, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei, Shinozaki, Eiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327308/
https://www.ncbi.nlm.nih.gov/pubmed/37415118
http://dx.doi.org/10.1186/s12885-023-11067-y
_version_ 1785069596261220352
author Fukuda, Koshiro
Osumi, Hiroki
Yoshino, Koichiro
Nakayama, Izuma
Fukuoka, Shota
Ogura, Mariko
Wakatsuki, Takeru
Ooki, Akira
Takahari, Daisuke
Chin, Keisho
Yamaguchi, Kensei
Shinozaki, Eiji
author_facet Fukuda, Koshiro
Osumi, Hiroki
Yoshino, Koichiro
Nakayama, Izuma
Fukuoka, Shota
Ogura, Mariko
Wakatsuki, Takeru
Ooki, Akira
Takahari, Daisuke
Chin, Keisho
Yamaguchi, Kensei
Shinozaki, Eiji
author_sort Fukuda, Koshiro
collection PubMed
description BACKGROUND: Few studies have focused on the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic colorectal cancer. Recognizing differences in prognosis and chemotherapeutic efficacy based on metastasized organs may help in optimizing treatment strategies. The exploratory study was conducted to evaluate the comparative clinical outcomes and prognoses of patients with metastatic colorectal cancer presenting with single-organ pulmonary metastases and treated with folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors as second-line chemotherapy. METHODS: This retrospective study included 289 patients with metastatic colorectal cancer treated with second-line folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors. The response rate, disease control rate, progression-free survival, and overall survival were assessed in the participants. RESULTS: Among the 289 patients enrolled, 26 (9.0%) had single-organ pulmonary metastasis with left-sided primary locations, lower levels of tumor markers at the initiation point of chemotherapy, a significantly higher disease control rate (96.2% vs. 76.7%, P = .02), and a longer progression-free survival (median 29.6 months vs. 6.1 months, P < .001) and overall survival (median 41.1 months vs. 18.7 months, P < .001) than patients with other forms of metastatic colorectal cancer. Multivariate analysis showed that single-organ pulmonary metastasis was an independent predictor of longer progression-free survival (hazard ratio 0.35, P = .00075) and overall survival (hazard ratio 0.2, P = .006). CONCLUSION: Single-organ pulmonary metastasis was a strong predictor of progression-free survival and overall survival in patients with metastatic colorectal cancer treated with folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors as second-line chemotherapy; this provides preliminary evidence for medical guidelines and clinical decision-making on novel therapeutic strategies for these patients.
format Online
Article
Text
id pubmed-10327308
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103273082023-07-08 Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors Fukuda, Koshiro Osumi, Hiroki Yoshino, Koichiro Nakayama, Izuma Fukuoka, Shota Ogura, Mariko Wakatsuki, Takeru Ooki, Akira Takahari, Daisuke Chin, Keisho Yamaguchi, Kensei Shinozaki, Eiji BMC Cancer Research BACKGROUND: Few studies have focused on the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic colorectal cancer. Recognizing differences in prognosis and chemotherapeutic efficacy based on metastasized organs may help in optimizing treatment strategies. The exploratory study was conducted to evaluate the comparative clinical outcomes and prognoses of patients with metastatic colorectal cancer presenting with single-organ pulmonary metastases and treated with folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors as second-line chemotherapy. METHODS: This retrospective study included 289 patients with metastatic colorectal cancer treated with second-line folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors. The response rate, disease control rate, progression-free survival, and overall survival were assessed in the participants. RESULTS: Among the 289 patients enrolled, 26 (9.0%) had single-organ pulmonary metastasis with left-sided primary locations, lower levels of tumor markers at the initiation point of chemotherapy, a significantly higher disease control rate (96.2% vs. 76.7%, P = .02), and a longer progression-free survival (median 29.6 months vs. 6.1 months, P < .001) and overall survival (median 41.1 months vs. 18.7 months, P < .001) than patients with other forms of metastatic colorectal cancer. Multivariate analysis showed that single-organ pulmonary metastasis was an independent predictor of longer progression-free survival (hazard ratio 0.35, P = .00075) and overall survival (hazard ratio 0.2, P = .006). CONCLUSION: Single-organ pulmonary metastasis was a strong predictor of progression-free survival and overall survival in patients with metastatic colorectal cancer treated with folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors as second-line chemotherapy; this provides preliminary evidence for medical guidelines and clinical decision-making on novel therapeutic strategies for these patients. BioMed Central 2023-07-06 /pmc/articles/PMC10327308/ /pubmed/37415118 http://dx.doi.org/10.1186/s12885-023-11067-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Fukuda, Koshiro
Osumi, Hiroki
Yoshino, Koichiro
Nakayama, Izuma
Fukuoka, Shota
Ogura, Mariko
Wakatsuki, Takeru
Ooki, Akira
Takahari, Daisuke
Chin, Keisho
Yamaguchi, Kensei
Shinozaki, Eiji
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors
title Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors
title_full Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors
title_fullStr Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors
title_full_unstemmed Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors
title_short Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors
title_sort single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with folfiri and vascular endothelial growth factor inhibitors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327308/
https://www.ncbi.nlm.nih.gov/pubmed/37415118
http://dx.doi.org/10.1186/s12885-023-11067-y
work_keys_str_mv AT fukudakoshiro singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors
AT osumihiroki singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors
AT yoshinokoichiro singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors
AT nakayamaizuma singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors
AT fukuokashota singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors
AT oguramariko singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors
AT wakatsukitakeru singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors
AT ookiakira singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors
AT takaharidaisuke singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors
AT chinkeisho singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors
AT yamaguchikensei singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors
AT shinozakieiji singleorganpulmonarymetastasisisafavorableprognosticfactorinmetastaticcolorectalcancerpatientstreatedwithfolfiriandvascularendothelialgrowthfactorinhibitors